Travere Therapeutics Inc (NAS:TVTX)
$ 6.16 -0.18 (-2.84%) Market Cap: 468.95 Mil Enterprise Value: 431.93 Mil PE Ratio: 0 PB Ratio: 6.33 GF Score: 54/100

Travere Therapeutics Inc Pegtibatinase in Classical Homocystinuria Phase 1/2 COMPOSE Study Results Call Transcript

May 31, 2023 / 12:30PM GMT
Release Date Price: $17.89 (+9.02%)
Operator

Hello, ladies and gentlemen, and thank you for standing by. Welcome to the Travere Therapeutics Corporate Update Call. I would now like to turn the call over to your host, Naomi Eichenbaum, Vice President of Investor Relations. Ms. Eichenbaum, please go ahead.

Naomi Eichenbaum

Thank you, Melinda, and thank you all for joining us today. Earlier today, we issued a press release covering the positive top line results from Cohort 6 in the Phase I/II COMPOSE Study of pegtibatinase in classical homocystinuria. A copy of the release, along with the slides that we'll be reviewing on today's call, are available on our Investor Relations website. Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Joining Eric will be our SVP of Research and Development, Dr. Bill Rote; and Dr. John Ficicioglu, MD, PhD, Clinical Director of the Metabolic Disease Program at Children's Hospital of Philadelphia. Our Chief Medical Officer, Dr. Jula Inrig, will also be available during the Q&A session.

Before we begin, I'd like to remind everyone that statements made

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot